Both Cellular Biomedicine Group Inc. (NASDAQ:CBMG) and Benitec Biopharma Limited (NASDAQ:BNTC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellular Biomedicine Group Inc.||N/A||1437.56||39.79M||-2.20||0.00|
|Benitec Biopharma Limited||N/A||0.00||N/A||-0.82||0.00|
Table 1 shows gross revenue, earnings per share and valuation of the two companies.
Table 2 shows the return on equity, net margins and return on assets of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Cellular Biomedicine Group Inc.||0.00%||-46.2%||-43.2%|
|Benitec Biopharma Limited||0.00%||0%||0%|
Recommendations and Ratings for Cellular Biomedicine Group Inc. and Benitec Biopharma Limited can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Cellular Biomedicine Group Inc.||0||0||1||3.00|
|Benitec Biopharma Limited||0||0||0||0.00|
Cellular Biomedicine Group Inc. has a consensus price target of $26, and a 56.16% upside potential.
Institutional & Insider Ownership
Institutional investors owned 19.3% of Cellular Biomedicine Group Inc. shares and 4.11% of Benitec Biopharma Limited shares. About 39.63% of Cellular Biomedicine Group Inc.’s share are owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Cellular Biomedicine Group Inc.||4.14%||6.13%||-7.28%||-5.94%||11.6%||6.8%|
|Benitec Biopharma Limited||32.73%||44.42%||-9.25%||-22.06%||-33.96%||46%|
For the past year Cellular Biomedicine Group Inc. has weaker performance than Benitec Biopharma Limited
Benitec Biopharma Limited beats Cellular Biomedicine Group Inc. on 5 of the 8 factors.
Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy. The company has a strategic research collaboration with GE Healthcare Life Sciences China to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. Cellular Biomedicine Group Inc. was incorporated in 2001 and is headquartered in Cupertino, California.
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.